Exagen Diagnostics, which sells diagnostic blood tests that detect lupus and rheumatoid arthritis, filed on Friday with the SEC to raise up to $69 million in an initial public offering. Primary shareholders include Sun Mountain Capital, Tullis Health...read more
T2 Biosystems, which is developing diagnostics tests that screen for sepsis and hemostasis, filed on Wednesday with the SEC to raise up to $69 million in an initial public offering. The company claims that its technology platform will lead to an earlier...read more
Quotient, which is developing a diagnostics test for grouping and disease screening blood samples, raised $40 million by offering 5.0 million shares at a price of $8, along with attached warrants to purchase 4 million shares at $8.80 per share. The company had...read more
Quotient, which is developing a diagnostics test for grouping and disease screening blood samples, lowered the proposed deal size for its upcoming IPO on Wednesday. The Midlothian, United Kingdom-based company now plans to raise $40 million by offering 5.0...read more
It's not lupus: Exagen Diagnostics files for a $69 million IPO
Exagen Diagnostics, which sells diagnostic blood tests that detect lupus and rheumatoid arthritis, filed on Friday with the SEC to raise up to $69 million in an initial public offering. Primary shareholders include Sun Mountain Capital, Tullis Health...read more
Diagnostics developer T2 Biosystems files for a $69 million IPO
T2 Biosystems, which is developing diagnostics tests that screen for sepsis and hemostasis, filed on Wednesday with the SEC to raise up to $69 million in an initial public offering. The company claims that its technology platform will lead to an earlier...read more
Quotient prices IPO at $8
Quotient, which is developing a diagnostics test for grouping and disease screening blood samples, raised $40 million by offering 5.0 million shares at a price of $8, along with attached warrants to purchase 4 million shares at $8.80 per share. The company had...read more
Quotient cuts proposed range and adds warrants
Quotient, which is developing a diagnostics test for grouping and disease screening blood samples, lowered the proposed deal size for its upcoming IPO on Wednesday. The Midlothian, United Kingdom-based company now plans to raise $40 million by offering 5.0...read more